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Strengths and limitations of this study
 ► A key strength of this study was measurement of 
shared decision-making (SDM) in clinical practice 
in teams that had embedded SDM in the National 
Health Service.
 ► The study used mixed methods to measure and 
explore SDM in clinical practice using observer, 
self-reported and qualitative assessments providing 
a multidimensional understanding.
 ► A limitation of this study was the use of the SureScore 
self-reported measure with discrete scoring options 
that resulted in ceiling effects.
AbStrACt
Objectives To examine how observer and self-report 
measures of shared decision-making (SDM) evaluate the 
decision-making activities that patients and clinicians 
undertake in routine consultations.
Design Multi-method study using observational and self-
reported measures of SDM and qualitative analysis.
Setting Breast care and predialysis teams who had 
already implemented SDM.
Participants Breast care consultants, clinical nurse 
specialists and patients who were making decisions 
about treatment for early-stage breast cancer. Predialysis 
clinical nurse specialists and patients who needed to make 
dialysis treatment decisions.
Methods Consultations were audio recorded, transcribed 
and thematically analysed. SDM was measured using 
Observer OPTION-5 and a dyadic SureScore self-reported 
measure.
results Twenty-two breast and 21 renal consultations 
were analysed. SureScore indicated that clinicians and 
patients felt SDM was occurring, but scores showed 
ceiling effects for most participants, making differentiation 
difficult. There was mismatch between SureScore and 
OPTION-5 score data, the latter showing that each 
consultation lacked at least some elements of SDM. 
Highest scoring items using OPTION-5 were ‘incorporating 
patient preferences into decisions’ for the breast team 
(mean 18.5, range 12.5–20, SD 2.39) and ‘eliciting patient 
preferences to options’ for the renal team (mean 16.15, 
range 10–20, SD 3.48). Thematic analysis identified 
that the SDM encounter is difficult to measure because 
decision-making is often distributed across encounters 
and time, with multiple people, it is contextually adapted 
and can involve multiple decisions.
Conclusions Self-reported measures can broadly 
indicate satisfaction with SDM, but do not tell us about the 
quality of the interaction and are unlikely to capture the 
multi-staged nature of the SDM process. Observational 
measures provide an indication of the extent to which 
elements of SDM are present in the observed consultation, 
but cannot explain why some elements might not be 
present or scored lower. Findings are important when 
considering measuring SDM in practice.
bACkgrOunD
There is strong policy support for the routine 
use of shared decision-making (SDM) in 
clinical practice,1 2 accompanied with an 
increasing need to identify if and how SDM 
is taking place. Theoretically during SDM, 
patients are encouraged to think about the 
available treatment options, and the associ-
ated pros and cons in relation to their own 
preferences. Patients and clinicians are 
expected to collaborate and make decisions 
together that are informed by the best avail-
able evidence and truly aligned with patient 
preferences.3 Incentives for doing SDM with 
patients are being considered to help over-
come some of the barriers associated with 
implementation.1 2 Therefore, for policy, 
there is a need to accurately measure SDM to 
identify whether it is happening and how it 
can be improved.
The National Institute for Health and 
Care Excellence’s ‘Shared Decision Making 
Collaborative’ recently published a compre-
hensive action plan for incorporating SDM 
into everyday care in the UK. This includes 
identifying strategies to successfully 
measure SDM in practice.2 The General 
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box 1 Content of SureScore measure
Dyadic SureScore
Completed individually after consultation by the patient and clinician.
Item description
Three questions in the patient version:
1. Did you discuss treatment options?
2. Did you discuss risks and benefits of different options?
3. Did you discuss what is important to you in your treatment?
Clinician version is identical, but questions are framed from the clini-
cian’s perspective.
response categories
Items were scored based on three discreet response categories to each 
item. Patients/clinicians were asked to indicate their answer by select-
ing either: Yes, Unsure, No.
Medical Council in the UK has also included SDM as a 
core professional competency in their updated generic 
professional capabilities framework.3 Assessing SDM 
capabilities places further value on the skill of sharing 
decisions with patients, and could encourage organ-
isational support and wider implementation of the 
approach.
If SDM is to become part of routine care, we need 
appropriate summative measurement methods; policy-
makers and healthcare managers will need to know if 
and how well clinicians are doing SDM in practice, its 
effects on clinical practice and the difference it makes to 
patients.2 However, there are risks of measurement tools 
not capturing SDM in practice correctly, not reflecting 
what SDM looks like in routine clinical practice. Theoret-
ical models do provide a useful framework for teaching 
and learning SDM skills, but there are a large number of 
clinician, patient and contextual factors, which will mean 
the SDM process will vary considerably between encoun-
ters. Further, SDM research and theory has tradition-
ally conceptualised the process as occurring in dyadic 
encounters during a specific consultation.4 However, 
healthcare decisions are often made in a distributed 
manner,4 across numerous consultations and/or with 
different clinicians and significant others (eg, family 
members). The influence of contextual factors and 
the distributed nature of decision-making is especially 
important if SDM measurement in clinical practice is 
to be implemented for inspection or incentive schemes. 
Many measurement tools are available,5–8 but there is 
currently no ‘gold standard’ for measuring SDM.9 10 If 
summative, policy-related measurement tools are to be 
routinely implemented, we need to be sure that the 
theoretically developed measurement instruments, and 
the theories on which they are based, can capture what 
happens in routine clinical care. The same also applies 
to measurement for formative purposes; for example, 
ensuring that continuing professional development 
reviews or personal learning for clinicians is based on 
what is achievable and practical in routine care.
The Making Good Decisions in Collaboration (MAGIC) 
learning programme9 was commissioned by The Health 
Foundation to examine how best to embed SDM in routine 
clinical care. The legacy of this programme was clinical 
teams who had routinely embedded this approach and 
SDM interventions. This current study aimed to examine 
if and how observer and self-report measures of SDM 
evaluate the decision-making activities that patients and 
clinicians undertake in routine consultations. Key objec-
tives included observing SDM in routine clinical settings 
with teams who have embedded the approach; examine 
if and how observer and self-report measures capture the 
SDM process; and compared and contrasted data from 
observer and self-report measures. The learning from this 
paper will be able to inform strategies for measuring SDM 
in routine clinical practice
MethODS
We conducted a multi-methods study to measure SDM 
in clinical practice in two routine secondary care settings 
in the UK that had already implemented SDM. Consulta-
tions audio recorded by clinicians over a period of time 
were passed to the research team and subsequently tran-
scribed verbatim. They were scored using OPTION-511 
and thematically analysed. Clinicians and patients were 
also asked to complete the SureScore (box 1) measure at 
the end of their consultations.
Participant recruitment
Clinical team recruitment
Two clinical teams where patients needed to make a key 
treatment decision were recruited within the Cardiff and 
Vale University Health Board (Wales, UK)—the Breast 
Care Centre and the Chronic Kidney Disease Predialysis 
team.
The Breast Care Centre key decision point was the 
decision between mastectomy or wide local excision with 
follow-up radiotherapy. The Chronic Kidney Disease 
Predialysis decision point concerned different types of 
dialysis and transplantation.
Both teams were previously trained in SDM and had 
embedded SDM as part of the 2010–2015 ‘Making Good 
Decisions in Collaboration’ (MAGIC) implementation 
programme.9 Most team members had attended theoret-
ical and practical SDM skills training workshops, based 
on the ‘3 Talk’ theoretical model SDM.12 Each team 
had also developed and implemented a brief in-consul-
tation decision support tool. All relevant clinical team 
members (eg, consultants, specialist nurses) who would 
consult with patients regarding treatment decisions were 
sent study information packs containing a cover letter, 
participant information sheet for clinicians and a consent 
form. Participation involved clinicians audio recording 
their consultations with patients and completing a post-
consultation questionnaire. Only consultations where the 
clinician and the patient had agreed to participate were 
recorded.
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box 2 Content of Observer OPtIOn-5 measure
We then compared all data to explore the ability of the different mea-
sures to measure the shared decision-making (SDM) process in routine 
clinical settings.
Observer OPtIOn-5
Completed by trained raters using audio recordings and verbatim tran-
scripts of the consultations
Item description of the Observer OPTION-5 measure:
1. Alternative options
Clinician draws attention to or confirms that alternative options exist/
need for a decision exists. Clinician responds by agreeing that options 
need deliberation if patient draws attention to availability of options.
2. Support deliberation
Clinician reassures/reaffirms the patient that they will support them to 
become informed/deliberate about options. If patient states they have 
sought information prior to consultation, the clinician supports the de-
liberative process.
3. Information and options
Clinician gives information and checks understanding about the options 
(including ‘no action’) to support the patient in comparing alternatives. 
Clinician supports any clarification needed by the patient.
4. Eliciting preferences
Clinician makes effort to elicit patient preferences in response to options 
presented. Clinician is supportive if patient declares their preferences.
5. Integrating preferences
Clinician makes effort to integrate patient preferences as decisions are 
made. If patient indicates how best to integrate their preferences into 
the decision, the clinician makes an effort to do so.
response categories
Each item was scored on a Likert scale from 0 to 4. Items were scored 
according to the OPTION-5 manual.28
0=No effort—not observed/heard.
1=Minimal effort—the use of short phrases that indicate the issue is 
being raised.
2=Moderate effort—more substantive talk used to discuss issues and 
ideas.
3=Skilled effort—substantive talk is used to convey the ideas and is-
sues, and understanding is checked.
4=Exemplary effort—excellent and careful attention to ideas and is-
sues, and understanding is checked.
Patient recruitment
Eligible patients were recruited consecutively by clini-
cians working in the predialysis team and Breast Care 
Centre between April 2014 and September 2015. Inclu-
sion criteria stipulated that patients needed to be over 
18 years old. Patients who were unable to communi-
cate in English or who were deemed unsuitable due to 
other vulnerabilities identified by the clinical team were 
excluded. All patients were provided with a study pack 
which included a cover letter, patient information sheet 
and consent form before their consultation.
Data collection
All consultations were audio recorded and transcribed 
verbatim. Observer OPTION-5 and the dyadic Sure-
Score measures were used to measure SDM in clinical 
practice during consultations. SureScore is a three-item 
self-reported questionnaire (Box 1), which captures 
both patients’ and clinicians’ perceptions of SDM during 
the consultation.11 The measure was adopted by the 
Cardiff and Vale University Health Board during the 
MAGIC implementation programme13 and integrated 
into routinely collected outpatient questionnaires. The 
observer measure of SDM (Observer OPTION-5) (Box 2) 
is a five-item measure based on the Model of Collab-
orative Deliberation,14 and is an update to the original 
OPTION-12 instrument.11 Observer OPTION-5 was used 
to independently assess the consultation audio recordings 
for elements of SDM.15 We also conducted thematic anal-
ysis of audio-recorded consultations to understand what 
the SDM process looked like in routine clinical settings, 
and to explore whether the measurement tools were able 
to adequately measure SDM in practice.16
Patient and public involvement
Patient and public representatives were involved in 
reviewing the study documents at the start of the MAGIC 
project. GH is a coauthor in this manuscript and the 
current patient and public representative. GH worked 
collaboratively with the research team to contribute to the 
content of the manuscript. GH shared her experiences of 
SDM in healthcare, commented on the manuscript and 
agreed on the final version.
Analysis
Quantitative analysis
OPTION-5: Each consultation audio recording and 
verbatim transcript was analysed independently by two 
trained raters (DW and NJW). The raters had under-
gone training (using the OPTION-5 manual) and a 
scoring and standardisation process where they read the 
OPTION-5 training manual (and contacted the measure’s 
developers with any queries). To ensure standardisation, 
raters scored 10 consultations each (five for each clinical 
area), met to compare agreement levels and resolved any 
discrepancies through discussion. DW is a psychologist 
with expertise in healthcare communication in women’s 
health and long-term conditions. NJW is a psychologist 
with expertise in SDM and patient-centred care.
Each item was scored on a 5-point Likert-like scale 
(0=no effort, 4=exemplary effort). The total OPTION-5 
score was calculated by adding up the scores of each item 
(score range 0–20) and it was then rescaled to range from 
0 to 100. Two raters scored all consultations, therefore 
the mean of the two scores was taken for each consul-
tation (out of a possible 100). Higher scores indicated 
that a greater number of SDM elements outlined by the 
measure were observed. Descriptive statistics were used to 
compare the mean scores between items and teams.
Items within the SureScore measure were analysed 
using SPSS for Windows V.22.17 Descriptive statistics were 
used to characterise the sample, and to observe the distri-
bution of responses to SureScore items and the pattern 
of missing data as an indicator of their acceptability to 
patients and clinicians. Cross-tabulations of patient and 
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Table 1 Clinician and patient scores on the SureScore survey for breast cancer and predialysis teams
Yes 
(Clinician)
Yes 
(Patient)
Unsure
(Clinician)
Unsure 
(Patient)
No
(Clinician)
No
(Patient) Missing
Item 1: Did 
you discuss 
the treatment 
option?
BrCa diagnostic 
consultation
25 25 0 0 0 0 0
BrCa follow-up 
consultation
22 22 0 0 0 0 3
Predialysis 
consultation
26 21 0 0 0 0 5
Item 2: Did you 
discuss the risks 
and benefits 
of treatment 
option?
BrCa diagnostic 
consultation
22 23 1 0 2 2 0
BrCa follow-up 
consultation
24 22 0 0 1 0 3
Predialysis 
consultation
25 20 1 1 0 0 5
Item 3: Did you 
discuss what is 
important in your 
treatment/to the 
patient in their 
treatment?
BrCa diagnostic 
consultation
22 22 0 2 3 1 0
BrCa follow-up 
consultation
25 22 0 0 0 0 3
Predialysis 
consultation
24 20 2 0 0 1 5
BrCa, breast cancer.
clinician responses were used to identify patients and 
clinicians with discordant scores.
Qualitative analysis
Consultation transcripts were transcribed verbatim and 
thematically analysed. The breast cancer (BrCa) and 
predialysis consultations were analysed separately. The 
data were analysed using Braun and Clarke’s approach 
to thematic analysis,18 which included familiarising with 
the data, generating initial codes, searching for themes, 
reviewing and refining themes, and defining and naming 
themes. DW conducted the data coding. Regular quali-
tative research team meetings were used to discuss the 
development of the coding framework and data analysis, 
with each member of the qualitative group (DW, NJW, FW, 
AE) adding their own unique perspective to the analysis19 
and resolving any discrepancies in coding through discus-
sion. An inductive approach was used in analysis to allow 
themes to emerge from the data in order to understand 
SDM. Data were not double coded, instead themes were 
discussed in team meetings to discuss data production, 
the development of the coding framework and data anal-
ysis. This approach has been identified as appropriate in 
qualitative research.19 We were guided by the concept of 
‘information power’20 rather than ‘saturation’.20 Informa-
tion power is determined iteratively by the aims, sample 
specificity, quality of dialogue and analytic strategy.20 
Sample size was iteratively determined reflexively based 
on the themes that were emerging through the data, and 
continued until no major new themes were being iden-
tified. Clinicians were informed when to stop collecting 
data based on the researchers’ assessment of information 
power. NVivo V.11 software was used to organise the data.
reSultS
Eleven members of the breast care team consented to 
participate in the study: four consultants/surgeons, one 
registrar, one consultant nurse and five clinical nurse 
specialists. All three clinical nurse specialists in the predi-
alysis team consented to participate in the study.
SDM in clinical practice was assessed during healthcare 
consultations in clinic or at patients’ home where treat-
ment options were discussed: this included one consul-
tation per patient with chronic kidney disease (CKD; 
predialysis consultation with the clinical nurse specialist), 
and two consultations per patient with BrCa (diagnostic 
consultation and follow-up visit, involving different team 
members). Twenty-six patients who had been referred to 
the predialysis team (16 males, 10 females) and 25 female 
patients with BrCa were recruited and had their consul-
tations audio recorded. Family members/friends were 
frequently present. The SureScore measure was returned 
by both the patient and clinician in 22 of the BrCa and 21 
of the predialysis consultations.
The self-reported SureScore questionnaire data 
showed that both patients and clinicians thought SDM 
was happening during their consultations (see table 1). 
Missing data represented five CKD and three follow-up 
patients with BrCa who had not returned the measure 
(therefore we had 47 surveys that were returned from 
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Table 2 Standardised (0–20) Observer OPTION-5 domain mean scores, SD, minimum and maximum scores for each item 
(n=25 breast cancer and n=26 predialysis consultations)
OPTION-5 item
Mean score, SD Minimum score Maximum score
Breast Renal Breast Renal Breast Renal
1. Alternative options 15, 3.60 11.05, 2.66 10 7.5 20 15
2. Support deliberation 12.5, 3.06 8.65, 2.79 7.5 5.0 20 15
3. Information about options 17.6, 2.22 16.05, 2.14 12.5 10 20 20
4. Eliciting preferences 17.7, 2.87 16.15, 3.48 10 10 20 20
5. Integrating preferences 18.5, 2.39 15.38, 3.65 12.5 7.5 20 20
both diagnostic and follow-up BrCa appointments and 21 
CKD surveys returned by both patients and clinicians).
A high proportion of respondents gave the maximum 
score, thus the instrument showed ceiling effects with 
limited variability in the data. There was little disagree-
ment in the responses between the clinicians and patients. 
All patients and clinicians felt that treatment options were 
discussed during all consultations. Both clinicians and 
patients responded ‘Yes’ on ‘Item 1: Did you discuss treat-
ment options?’ for both diagnostic and follow-up breast 
care consultations and predialysis consultations.
Most patients (45/50 BrCa and 20/26 CKD) and clini-
cians (46/50 BrCa and 25/26 CKD) felt that the risks 
and benefits of treatment options were discussed during 
consultations, scoring ‘Yes’ on item 2: ‘Did you discuss the 
risks and benefits of treatment options?’ On three occa-
sions, it was felt that risks and benefits were not discussed 
in the breast care sample, where three clinicians and two 
patients scored ‘No’.
The vast majority of patients and clinicians in the 
predialysis team scored that the risks and benefits of the 
treatment options were discussed (20/21 and 25/26, 
respectively).
The minority of consultations scored as ‘No’ (BrCa 
clinician n=3, patient n=1) or ‘Unsure’ (patient with CKD 
n=1) by the clinicians or patients were inspected in more 
detail using the OPTION-5 data and thematic analysis. It 
was found that there was a lack of in-depth discussion of 
risks and benefits in these consultations, usually due to a 
number of factors such as distress of the patient during 
the consultation necessitating alternative discussions, or 
an early and strong indication of treatment preference by 
a well-informed patient.
Most patients (BrCa n=44, CKD n=20) and clinicians 
(BrCa n=47, CKD n=24) felt they had discussed what 
was important to the patient regarding their treatment 
in both the BrCa and predialysis consultations (item 
3). Three clinicians and one patient felt they had not 
discussed what was important to the individual during the 
diagnostic breast consultation as well as one patient in the 
predialysis consultation.
The Observer OPTION-5 data provided more details. 
Predialysis consultations ranged from 50 min to 2 hours 
and 25 min (mean 1 hour and 35 min). Breast diagnostic 
consultations ranged from 19 min to 1 hour and 4 min 
(mean 33 min), follow-up consultations ranged from 14 
min to 1 hour and 38 min (mean 51 min).
Elements of theoretical SDM were present in all 
consultations. Standardised global OPTION-5 scores 
ranged from 65.0 to 95.0 with a mean of 82.82 (SD 
8.54) for the breast care consultations, and 47.50–80.0 
with a mean score of 66.53 (SD 9.16) for the predialysis 
consultations.
Standardised scores for each item and team are 
presented in table 2. Differences in mean scores between 
items were observed with option presentation (item 3), 
preference elicitation (item 4) and preference integra-
tion (item 5) scoring consistently highest across both 
teams. Item 2, which looks at the extent to which the 
clinician reassured the patient that they were there to 
help support them to become informed and to deliberate 
over their treatment options, was consistently given a low 
score. Introduction of choice (item 1) also tended to 
score lower, suggesting it was not completed as compre-
hensively as the other SDM skills.
By listening to the consultation audio recordings, it was 
clear that the implicit and unspoken understandings that 
occur across consultations are difficult for an assessor 
to score. For example, when clinicians had previously 
spoken to patients over the telephone when making an 
appointment and had outlined the rationale for offering 
a choice. Supportive SDM tasks in clinical practice were 
often implicit and broader than the instrument assessed. 
Lower scores on item 2 were likely to have resulted from 
the instrument’s inability to capture embedded and 
unspoken understandings, and did not reflect the actual 
support offered. The fact that the clinician was spending 
a long time outlining treatment options, discussing pros 
and cons as well as eliciting preferences implied that they 
were supportive of the patient. This is implicit support. 
Item 2 specifically states that a high score can only be 
given if support is offered explicitly, ‘The clinician reas-
sures the patient or re-affirms that the clinician will 
support the patient to become informed or deliberate 
about the options.’
A summary of the ability of the SureScore and 
OPTION-5 measures to capture SDM in clinical practice 
is shown in table 3.
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Table 3 Measurement of SDM in clinical practice using self-report and observational tools
Measurement tool type What it does What it does not do Potential problems
Self-report questionnaire Broadly inform us if patients/
clinicians felt that SDM was 
occurring.
Relatively easy to implement.
It is unable to tell us about the 
quality of the interaction.
It is unlikely to provide an 
accurate representation of the 
‘distributed’ SDM process.
Susceptible to the ‘halo 
effect’, social desirability 
and response bias.
Observational measure Provides an indication of the 
extent to which elements of 
theoretical SDM are present in a 
consultation.
It does not account for why 
some elements of SDM are 
not observed or scored lower.
It can only capture what 
is observed at the time of 
measurement, and does not 
account for the ‘distributed’ 
process of SDM.
Time and resource 
intensive.
Needs specialist 
equipment, for example, 
audio/visual recorder.
Can only be completed by 
trained raters.
SDM, shared decision-making.
thematic analysis
Thematic analysis was performed on 25 BrCa consul-
tations (diagnosis and follow-up) and 26 predialysis 
consultations. The aim of the thematic analysis was to 
explore SDM in clinical practice and to reflect this on 
the measurement tools. BrCa and predialysis consulta-
tions were analysed separately but due to similarities in 
themes emerging, results for both are presented below. 
An increasingly complex picture of the processes during 
SDM in clinical practice emerged when we examined the 
audio recordings of healthcare consultations—a picture 
that was not fully captured by either the self-reported or 
observer measures of theoretical SDM that we used. Three 
broad themes were identified which measurement tools 
were not fully responsive to: distributed SDM, multiple 
and interacting decisions and the contextually adapted 
process of SDM. Each theme will be discussed below.
Distributed SDM
SDM in clinical practice was ‘distributed’ over people and 
time across a number of consultations, involving multiple 
clinicians, the patient and their family members, and 
sometimes over a prolonged period of time. Quite often, 
a decision did not need to be made within one specific 
consultation. In the breast care team, treatment options 
were presented by the consultant during the diagnostic 
consultation. They were then discussed further during 
a follow-up consultation 1 week later with the specialist 
nurse, which was when a treatment decision was typically 
made.
Okay. Well remember when you saw [consultant 
name] in the clinic last week, he said to you it’s per-
fectly simple, there's an option of surgery. The first 
option being that we can remove the lump with the 
margin of tissue around it and then give you a course 
of radiotherapy and it’s that course of radiotherapy 
with just removing the lump that makes that as safe 
as having the whole breast removed the mastectomy. 
(Clinical nurse specialist, breast cancer follow-up, ID 
2.14)
The ‘preference elicitation’ process was initiated during 
the diagnostic consultation, when patients were sign-
posted to think about what mattered most to them, but 
the discussion of preferences typically occurred during 
the follow-up appointment.
Predialysis treatment discussions were distributed 
between consultants and predialysis nurses, and between 
patients and their family. Discussions around the initia-
tion of treatment decision processes had often started 
before the predialysis appointment which we measured, 
and the final decision was made some time later. Unlike 
the BrCa decisions, these decisions were also not defin-
itive as patients could review and revise their decision, 
making it particularly difficult to capture the SDM process 
that clinicians and patients were doing.
Okay, so just to let you know we'll see you back in clin-
ic in a month's time (…) Please ring me if you've got 
any questions, don’t sit at home and think mmm, but 
I am quite happy at the moment to just keep an eye 
on you. We don’t need to do anything. The only thing 
I’ll urge you, think about transplantation and have a 
read of the information. Don’t have to do it obviously 
in the next week or two but before you come back 
in a month’s time, have a think about transplant be-
cause I will be asking you. Ordinarily I refer patients 
straight away for transplant but I think you just need 
to have a little bit of time, because it is a new concept 
to you isn’t it? (Clinical nurse specialist, predialysis 
consultation, ID 1.17)
Multiple and interacting decisions
Patients were often required to make multiple decisions 
in relation to one condition. For example, although 
the focus of the consultation for patients with BrCa 
was the type of breast surgery, several reconstructive or 
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prosthesis options available were also discussed. Patients 
with CKD were considering dialysis as well as transplanta-
tion options. Patients were typically making multiple and 
interacting decisions; the outcomes of a later treatment 
option quite often influenced their decisions about initial 
treatment options (eg, outcomes of breast reconstructive 
options and choice of surgery). This complicated the 
preference elicitation and consolidation processes.
Patient: So if I had a mastectomy would I be able to 
have reconstruction?
Consultant: Yes, we do reconstruction, yeah. We do.
Patient: Do you do that straight after the operation?
Consultant: Yeah, we normally do. We normally do, 
yes. Um, the only thing that might affect that is if um, 
ah, this radiation issue again, if the um, for instance 
if there are lymph gland problems or anything like 
that there might be a recommendation that you have 
radiation. So, um, if you do have radiation as well as 
a mastectomy, which is, you don’t often have to have 
that, we then have to think about would that fit in well 
with immediate reconstruction?
Patient: I see.
Consultant: So often in that situation, if we think 
you’re going to have radiation then, um, we might 
say well, um, let’s leave the reconstruction till later.
Contextually adapted process of SDM
Patients’ previous knowledge about the condition and 
available treatment options also influenced the deci-
sion-making process. Sometimes previous knowledge 
and experience informed the patients’ prior preferences, 
where the patients expressed preferences before the 
treatment options had been presented for their current 
diagnosis.
Nurse: Okay, right, if I go through the operation, I 
know you said right from the start you know exactly 
which operation you want.
Patient: I do.
Nurse: And I have no wish to change your mind on 
that but I just want to make sure that I know you know 
all the pros and cons so that afterwards you don’t turn 
‘round and think oh if I’d known that I wouldn’t have 
made that decision. (Breast cancer follow-up visit, ID 
2.7)
The amount of information about options that was 
presented by clinicians varied based on the patient’s 
previous knowledge about the options, as well as their 
emotional response. For example, some patients were 
understandably emotionally distressed following their 
diagnosis of BrCa. In such cases, clinicians would some-
times limit the depth of information offered at that 
appointment and would defer in-depth explanations to 
the follow-up appointment.
Patients sometimes recalled information regarding 
treatment options based on their previous experiences 
(eg, recurring BrCa), as well as experiences of significant 
others who had received treatment and used these to 
contextualise perceived pros and cons.
My sister had two breasts removed at the same time, 
so it was a double…and my friend at the end of the 
street she’s got this [breast cancer]. I was talking to 
her on Friday…but the only thing is, she’s got it ob-
viously on the one side, and it was really noticeable 
[the mastectomy]…that’s why I thought, obviously 
with the two [breasts], am I going to match? (Patient, 
breast cancer diagnostic consultation, ID 2.3)
In predialysis consultations, some patients had exten-
sive knowledge and experiences of treatment options 
because of their family members’ experiences of dialysis. 
In these circumstances, the clinicians often altered the 
amount of information presented to patients, based on 
their previous knowledge.
Furthermore, the SDM process was also related to the 
context of the consultation. During the BrCa consulta-
tions, patients needed to make a decision relating to their 
imminent surgery. However, especially in the predialysis 
consultations, there was often no set time within which 
a decision needed to be made, because initiation of dial-
ysis would be dependent on the patient’s gradual renal 
deterioration. Therefore, during the predialysis consulta-
tions there was sometimes no evidence of incorporating 
patients’ preferences into the decision, as no decision was 
being made at this time.
Patient: Can I just ask you, you’re putting this across 
as this is imminent, that I’m going to have to go 
through this?
Nurse: Yes
Patient: Or are you just advising me and…
Nurse: Usually if I come to do a home visit, at some 
stage you will start on this treatment.
Patient: Really?
Nurse: It could be six months, it could be twelve 
months, it could be eighteen months. But what we 
want to do is … prepare you for it.
(Predialysis consultation, ID 1.13)
Overall, we found that the SDM in clinical practice 
process was not standardised or consistent—it was contin-
ually adapted to contextual factors and was therefore 
very difficult to capture using self-reported or observer 
measures. This has raised significant challenges that must 
be considered when trying to measure SDM. A summary 
of the key measurement challenges in clinical practice is 
presented in table 4.
DISCuSSIOn
In our observations we found that the observational and 
self-report measures we used were unable to fully capture 
the SDM process in clinical practice. This was because 
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Table 4 Shared decision-making in clinical practice and associated measurement challenges
Observations of SDM in clinical practice Measurement challenges
SDM is 
distributed over 
people and time.
SDM often involves different healthcare 
professionals and multiple consultations, 
especially in long-term conditions, for example, 
how many interactions (appointments/telephone 
calls) and with which clinicians?
SDM measurement tools are often based on theoretical 
models of SDM and require that all SDM stages are 
covered within one encounter. However, clinicians 
continually adapt their SDM approach to match the 
patient journey and a consultation which does not cover 
all aspects of SDM is not necessarily reflective of a poor 
SDM encounter.
Individuals using scores from an SDM encounter need 
to be aware of the patient’s journey through the health 
system.
SDM involves 
multi-staged 
decisions.
Patients are often required to make multiple 
decisions in relation to one condition, resulting in 
the decision-making process not being discrete 
or orderly.
SDM measurement tools generally focus on the process 
of reaching one particular decision. In the absence of 
‘discrete’ and ‘orderly’ decisions, together with the 
increasing incidence of patients with comorbidities, it 
raises the question of ‘which decision are we measuring?’
SDM is adapted 
to context.
The content of SDM consultations will 
vary based on the nature of the decision, 
for example, short term versus long term, 
the patient’s emotional response, previous 
knowledge and experiences of the treatment 
options.
Careful interpretation of measures is needed because a 
low item score does not necessarily mean a poor SDM 
consultation occurred; it might reflect the modification of 
content based on the context.
SDM, shared decision-making.
we observed SDM in clinical practice which was defined 
by multiple and staged decisions. This is similar to other 
studies4 who have described SDM as ‘distributed’. We 
found that SDM discussions were frequently distributed 
between consultations and healthcare professionals.
The observed mean OPTION-5 scores in this study were 
high compared with other studies that have used the tool 
to measure SDM in trained clinicians21 and the difference 
was higher than in clinicians who had not been trained 
in SDM.22 Furthermore, the OPTION-5 data showed 
that the BrCa team had higher mean scores than the 
CKD team. Based on theoretical models of SDM, these 
data might be interpreted that the CKD team was not as 
skilled in SDM as the BrCa team, but qualitative analysis 
suggested this was not the case. The Observer OPTION-5 
scores did not provide an accurate representation of the 
quality of SDM in the consultations, as some of the SDM 
tasks scored by the instrument were not appropriate for 
that specific consultation. If achieving SDM in clinical 
practice is not a standardised process, and it is continually 
adapted for contextual factors for that specific patient at 
that time, how can we use standardised instruments that 
are not responsive to these processes? Overall, OPTION-5 
provided a better indication of which parts of the process 
happened, and how well they were done, compared with 
SureScore, and it also highlighted what was not done so 
well or was missing. Observer measures of SDM are also 
less affected by ceiling effects or social desirability bias 
because they are completed by a third party.23
The data also suggested that self-report measures might 
be susceptible to the ‘halo effect’,23 where patients were 
reporting a good overall impression of the clinician 
because they liked them. Social desirability bias might 
have also influenced responses, reflecting key barriers 
to effective measurement that have been reported else-
where.24 Clinicians may also have been susceptible to 
response bias or were limited by the response categories 
present in the measure. Other self-report measures such 
as CollaboRATE25 use ordinal rating scales instead to 
score SDM during consultations, with responses ranging 
from ‘no effort was made’ to ‘every effort was made’. 
Although scales have also been criticised for ceiling effects 
in general,26 such measures do provide a larger range of 
response categories and therefore might be more sensi-
tive to reporting the full range of patient experience.
SureScore provided a broad indication of whether 
SDM in practice was thought to have happened or not, 
but it did not indicate the ‘quality’ of the SDM discussion 
(ie, Were the options discussed in a way that the patient 
fully understood?), or how the SDM process unfolded 
(ie, Did the patient or the clinician initiate the ‘shared’ 
discussion?). Self-reported measures also ask the patient 
to score a consultation based on the assumption that 
patients know what an SDM consultation might or should 
look like (although they may have never experienced 
one).
The detailed thematic analysis provided a richer under-
standing of what actually happens during SDM encoun-
ters between clinicians trained in SDM skills and their 
patients. We found that the Observer OPTION-5 instru-
ment was somewhat insensitive to contextual factors, such 
as patients’ prior knowledge or experience of treatment 
options. We also observed that predialysis consultations 
rarely covered the core SDM skill of ‘decision talk’19—they 
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were better characterised by ‘planning talk’, as a decision 
was rarely made at this point.
Detailed thematic analysis showed that the SDM 
encounter in clinical practice was distributed, and it iden-
tified it was contextually adapted and that individuals 
would often need to make multiple and interacting deci-
sions (as explained in table 4). We identified that some 
patients already had predetermined treatment prefer-
ences. In such situations it is important to acknowledge 
that for SDM to occur, the clinician needs to understand 
the reasoning behind the treatment preference. Clini-
cians should be encouraged to explore how the treat-
ment preference meets with patient goals, as well as 
their understanding of associated pros and cons. If the 
treatment preference meets the goals of the patient and 
if their understanding of the pros and cons is accurate, 
then the consultation should be seen as a process of SDM.
We observed that the process of SDM is distributed and 
adapted across consultations and clinicians and this poses 
important questions about when we should be measuring 
whether SDM took place, and whom we are assessing. 
Although the OPTION-5 measure could be used to 
capture SDM over time, by recording multiple visits, and 
scores, collecting these data might be unfeasible within 
the context of clinical practice. Alternatively, choosing 
one of the consultations to measure could lead to an 
unfair representation of the whole process (eg, incorpo-
ration of the patient’s preferences into the decision could 
happen at a later consultation), but measuring every 
consultation is perhaps not feasible and incurs more work 
for the patient if relying on self-report.27 If different clini-
cians are involved in the process, it might be difficult for 
patients to respond using the self-report measures, partic-
ularly if the ‘quality’ or ‘level’ of SDM differs between the 
clinicians (who should they be scoring?).
If we want to introduce routine measurement of SDM 
in clinical practice for inspection, incentive or forma-
tive purposes, we need to develop and validate new 
tools, or modify existing measures, to account for the 
distributed and personalised nature of SDM discussions 
within everyday clinical practice. The challenge will be 
to develop a measure that is responsive to the non-stan-
dardised nature of the SDM process, while also being 
generic enough to be easily administered and incorpo-
rated into routine healthcare practice and evaluation. It 
might be useful to have two types of SDM measurement 
tools, one type focusing on more discrete SDM discus-
sions (eg, contraception choice within general practice, 
or surgical choices), and another for long-term condi-
tions, which is particularly sensitive to the distributed 
nature of SDM and context.
It is often said that ‘what gets measured gets done,’ but 
when trying to monitor whether every patient is involved 
in their healthcare decisions, we must be cautious. 
Attempting to standardise the measurement of SDM, 
which is a highly contextualised process, is problematic. 
We must reflect on the purpose of measurement and what 
needs to be standardised. Theoretically, SDM requires 
that patients be aware of the options available to them, the 
associated benefits and barriers and that their personal 
preferences are elicited and incorporated within clinical 
practice. However, the process of achieving SDM in prac-
tice is adapted and contextually specific. Measuring SDM 
in routine practice is challenging, and caution is needed 
when using instruments that only capture a ‘snapshot’ 
of the entire process. We may instead focus on stan-
dardising the process of measurement for the purpose 
of improving SDM in clinical practice—that is, where 
and how often it is integrated into practice and how the 
data are made available for feedback and reflection. We 
may also consider measuring SDM at the endpoint of 
any given treatment decision or pathway, when the SDM 
process should have been completed, although caution 
is required as to what and whom patients are evaluating 
then. It is unlikely that one measure will ever be able to 
cover all clinical encounters which are very diverse in 
nature. SDM is often distributed over time, multistaged 
and context specific. The complex nature of SDM in clin-
ical practice poses significant measurement challenges, 
and it is unlikely that one instrument will ever be able to 
account for all these complexities. Instead, we need to 
use an appropriate combination of instruments suitable 
for the clinical context in question. This might include 
observational measurement, self-report and/or qualita-
tive analysis.
limitations
As well as the limitations relating to the measurement 
tools used in this study which were discussed above, a 
number of additional limitations need to be considered. 
This study did not explore the ability of SDM measure-
ment tools to capture SDM in consultations where discrete 
decisions are made, such as consultations focusing on 
contraception where a decision would likely be made at 
the end of the consultation. The Observer OPTION-5 
and SureScore measures might have been able to capture 
the SDM process in the consultation more effectively. 
Further, we did not observe clinicians who had either not 
been trained in SDM or those who have recently been 
trained, we focused on clinicians who had been trained 
in SDM through an SDM implementation research study.
This study was conducted as an implementation study 
in a clinical setting and did not have control measures 
associated with typical research studies (eg, as in 
randomised controlled trials). Therefore, because the 
clinical team members recruited patients into the study 
sequentially and directly sent the consultation recordings 
to the research team, it cannot be guaranteed that this 
was done in a completely unbiased way. Nevertheless, we 
observed consultations that did not score highly on the 
Observer OPTION-5 measure, which gives us confidence 
that we were not sent a biased set of consultations. We 
were also unable to provide a response rate relating to 
how many patients were approached to take part and how 
many declined.
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COnCluSIOn
SDM in clinical practice is a distributed, multistaged 
and context-specific process and current measures fail 
to account for the whole process, especially in long-term 
conditions. Current measures can provide some useful 
information on whether SDM is taking place, and how 
well it is done (eg, for formative evaluations used in 
continuing professional development). However, given 
the limitations identified by this study, further work is 
needed before summative assessments are routinely 
implemented in clinical practice, to make sure they 
account for the complex, adaptive and distributed nature 
of the process. This is especially important if summative 
tools are used for the purposes of incentivisation.
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